TY - JOUR
T1 - Can genetic-based advice help you lose weight? Findings from the Food4Me European randomized controlled trial
AU - Celis-Morales, Carlos
AU - Marsaux, Cyril F. M.
AU - Livingstone, Katherine M.
AU - Navas-Carretero, Santiago
AU - San-Cristobal, Rodrigo
AU - Fallaize, Rosalind
AU - Macready, Anna L.
AU - O'Donovan, Clare
AU - Woolhead, Clara
AU - Forster, Hannah
AU - Kolossa, Silvia
AU - Daniel, Hannelore
AU - Moschonis, George
AU - Mavrogianni, Christina
AU - Manios, Yannis
AU - Surwillo, Agnieszka
AU - Traczyk, Iwona
AU - Drevon, Christian A.
AU - Grimaldi, Keith
AU - Bouwman, Jildau
AU - Gibney, Mike J.
AU - Walsh, Marianne C.
AU - Gibney, Eileen R.
AU - Brennan, Lorraine
AU - Lovegrove, Julie A.
AU - Alfredo Martinez, J.
AU - Saris, Wim H. M.
AU - Mathers, John C.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Background: There has been limited evidence about whether genotype-tailored advice provides extra benefits in reducing obesity-related traits compared with the benefits of conventional one-size-fitsall advice.Objective: We determined whether the disclosure of information on fat-mass and obesity-associated (FTO) genotype risk had a greater effect on a reduction of obesity-related traits in risk carriers than in nonrisk carriers across different levels of personalized nutrition.Design: A total of 683 participants (women: 51%; age range: 18-73 y) from the Food4Me randomized controlled trial were included in this analysis. Participants were randomly assigned to 4 intervention arms as follows: level 0, control group; level 1, dietary group; level 2, phenotype group; and level 3, genetic group. FTO (single nucleotide polymorphism rs9939609) was genotyped at baseline in all participants, but only subjects who were randomly assigned to level 3 were informed about their genotypes. Level 3 participants were stratified into risk carriers (AA/AT) and nonrisk carriers (TT) of the FTO gene for analyses. Height, weight, and waist circumference (WC) were self-measured and reported at baseline and months 3 and 6.Results: Changes in adiposity markers were greater in participants who were informed that they carried the FTO risk allele (level 3 AT/AA carriers) than in the nonpersonalized group (level 0) but not in the other personalized groups (level 1 and 2). Mean reductions in weight and WC at month 6 were greater for FTO risk carriers than for noncarriers in the level 3 group [-2.28 kg (95% CI: -3.06, -1.48 kg) compared with -1.99 kg (-2.19, -0.19 kg), respectively (P = 0.037); and -4.34 cm (-5.63, -3.08 cm) compared with -1.99 cm (-4.04, -0.05 cm), respectively, (P = 0.048)].Conclusions: There are greater body weight and WC reductions in risk carriers than in nonrisk carriers of the FTO gene.
AB - Background: There has been limited evidence about whether genotype-tailored advice provides extra benefits in reducing obesity-related traits compared with the benefits of conventional one-size-fitsall advice.Objective: We determined whether the disclosure of information on fat-mass and obesity-associated (FTO) genotype risk had a greater effect on a reduction of obesity-related traits in risk carriers than in nonrisk carriers across different levels of personalized nutrition.Design: A total of 683 participants (women: 51%; age range: 18-73 y) from the Food4Me randomized controlled trial were included in this analysis. Participants were randomly assigned to 4 intervention arms as follows: level 0, control group; level 1, dietary group; level 2, phenotype group; and level 3, genetic group. FTO (single nucleotide polymorphism rs9939609) was genotyped at baseline in all participants, but only subjects who were randomly assigned to level 3 were informed about their genotypes. Level 3 participants were stratified into risk carriers (AA/AT) and nonrisk carriers (TT) of the FTO gene for analyses. Height, weight, and waist circumference (WC) were self-measured and reported at baseline and months 3 and 6.Results: Changes in adiposity markers were greater in participants who were informed that they carried the FTO risk allele (level 3 AT/AA carriers) than in the nonpersonalized group (level 0) but not in the other personalized groups (level 1 and 2). Mean reductions in weight and WC at month 6 were greater for FTO risk carriers than for noncarriers in the level 3 group [-2.28 kg (95% CI: -3.06, -1.48 kg) compared with -1.99 kg (-2.19, -0.19 kg), respectively (P = 0.037); and -4.34 cm (-5.63, -3.08 cm) compared with -1.99 cm (-4.04, -0.05 cm), respectively, (P = 0.048)].Conclusions: There are greater body weight and WC reductions in risk carriers than in nonrisk carriers of the FTO gene.
KW - FTO
KW - genotype
KW - personalized nutrition
KW - randomized controlled trial
KW - weight
KW - BODY-MASS INDEX
KW - PHYSICAL-ACTIVITY
KW - PERSONALIZED NUTRITION
KW - OBESITY
KW - INTERVENTIONS
KW - INTERNET
KW - ADULTS
KW - WEB
KW - TECHNOLOGY
U2 - 10.3945/ajcn.116.145680
DO - 10.3945/ajcn.116.145680
M3 - Article
C2 - 28381478
SN - 0002-9165
VL - 105
SP - 1204
EP - 1213
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
IS - 5
ER -